HHC is controlled everywhere in Europe, and now worldwide

Short answer: there is no longer a European country where HHC is unregulated. On 6 December 2025 it came under international control, listed in Schedule II of the 1971 Convention on Psychotropic Substances. Every state party to that convention is obliged to control it, and that includes the United Kingdom and every EU member state.

Before that date the picture was a patchwork of national bans with different dates. After it, the question “which country is it still legal in?” has no answer left inside the convention system. That is the part almost no shop mentions, and it is the part that closes the file.

What HHC actually is

The confusion between HHC and CBD was kept alive by the shops that sold both. Chemically they are two very different things, and the difference explains why their legal paths ran in opposite directions.

A manufactured molecule, not an extracted one

HHC — hexahydrocannabinol — is a semi-synthetic cannabinoid. It is produced by hydrogenating a starting cannabinoid in a laboratory. Hydrogenation removes a double bond from the structure, which makes the molecule more stable against heat and light than THC and changes its activity profile.

CBD, by contrast, is extracted from the plant. That difference in origin is not administrative trivia: it is the reason one stayed on the market and the other left it.

Two forms inside the same product

Hydrogenation does not yield a single molecule but a mixture of two epimers, designated (9R)-HHC and (9S)-HHC, whose activity differs markedly. The ratio between them varies from batch to batch depending on the process. Two products declaring the same HHC percentage could therefore not be equivalent, and no rule required anyone to measure it.

Why it appeared on the market

Because it was not named on any list. Controlled-substance schedules work by enumeration: a molecule absent from the list escapes classification whatever it does. HHC was sold as a legal alternative, often with psychoactive effects described as close to those of THC.

Why that was never a guarantee

A substance being unnamed means nobody has assessed it yet — not that it has been judged acceptable. That distinction is enormous, and the trade leaned on it for roughly eighteen months.

Why it was banned

Health authorities reacted to two findings at once, and it is worth stating them precisely because they are usually reported the wrong way round.

A real psychoactive effect

HHC was not banned because it resembles CBD. It was banned precisely because it does not. CBD remains legal because it is not psychotropic — the reasoning the Court of Justice of the European Union settled in the Kanavape judgment.

An absence of safety data

No complete toxicological assessment existed when the product reached the market. It was consumed before it was studied, which is the reverse of the order the novel food regulation imposes on any new ingredient.

A speed that outran the registers

Months, not years, passed between commercial launch and the first national ban. No surveillance system was designed to move at that pace, and the first reports arrived when the product was already on shelves.

What that demonstrated

That the argument “it isn’t on the list” describes an administrative delay, not a favourable assessment. It is worth remembering the next time a new acronym turns up.

How the United Kingdom handles it

The UK approach differs from the continental one in a way that matters, and it is the source of a lot of bad information.

The list is not the mechanism

The Psychoactive Substances Act 2016 works by effect rather than by name. A substance produced for human consumption and capable of producing a psychoactive effect falls inside it unless it is specifically exempted. Waiting for a substance to be added to a list, as continental systems do, is not how the British statute is built.

What that means in practice

Producing, supplying, offering to supply, importing or exporting such a substance is an offence. The absence of a molecule’s name from any schedule does not create a gap here, because the statute never depended on the name in the first place.

Where the international listing fits

The United Kingdom is a party to the 1971 Convention, so the December 2025 listing applies to it as it does to every other state party. The two mechanisms overlap rather than compete.

What we are not doing here

We are not giving legal advice. We describe the state of the rules with the date attached. Anyone who needs an assessment of their own situation should get it from a solicitor, not from a product page.

Europe closed, country by country

What the chronology says

That HHC was never “legal in Europe”. It was unscheduled for about eighteen months, then scheduled almost everywhere, on different dates. The accurate word is unscheduled, and the distance from “legal” is exactly the distance between a gap and a permission.

The Polish case, precisely

Poland does not name HHC in its national schedules, and several shops build an argument on that. It is not a guarantee of lawfulness: the Schedule II listing under the 1971 Convention, in force since 6 December 2025, obliges every state party to control the substance, and Poland is one.

Our position

We reference no product from this family, in any market. This page exists to answer the question, not to accompany a sale.

The UN decision of 2025

This is what ended the question “which country is it still legal in?”.

What was decided

The United Nations Commission on Narcotic Drugs, meeting from 10 to 14 March 2025 for its 68th session, decided to list HHC in Schedule II of the 1971 Convention on psychotropic substances.

When it took effect

Notification went to the states parties on 9 June 2025, and the listing entered into force on 6 December 2025, at the end of the one-hundred-and-eighty-day period the convention provides.

Why it is a first

HHC is the first semi-synthetic cannabinoid placed under international control. Reported by 23 European countries and territories in 2022, it was reported by 56 worldwide by the time of the decision. The listing binds every state party: it stopped being a national grey area.

What follows from it

That searching for a permissive country no longer has an answer inside the convention system. A shop still promising trouble-free delivery is describing its own risk appetite, not the law of the destination country.

Why some shops still ship

It is the most common question, and the answer is not that the rules contain a hidden exception.

Because the risk moved

It sits with the recipient. As long as a share of parcels arrives, a business exists — even though the intercepted share exists too.

Because the catalogue changes names

Acronyms rotate every few months. As soon as one molecule is named on a schedule, the catalogue reappears with another that is not yet named, and the cycle starts again.

Because the country of dispatch misleads

A shipment from a state with a less current schedule looks like proof of legality. The law of the destination country is what counts, and the dispatch country is usually buried in the shipping terms rather than shown on the product page.

How to spot it in five seconds

If a shop is offering HHC with delivery in 2026, you already know it is not checking its catalogue against the schedules. It is the cheapest signal you will ever get about how a seller works.

How to recognise a shop that still sells it

This works as a general test well beyond this family of molecules: a shop that has not updated its catalogue has not updated anything else either.

An unusual dispatch country

Written small, in the shipping terms, and almost never on the product page. Worth checking before ordering rather than after.

Molecule names that rotate quarterly

If the catalogue from six months ago and today’s share a layout but not the acronyms, what you are looking at is a race against the schedules, not a product range.

No batch certificate

Without a per-batch analysis there is no way to know what is in the package. In this product family the absence was the norm, and that fact alone describes the seller’s standard.

A percentage with no milligrams

The percentage depends on the container volume and allows nothing to be compared. When the total mass is missing, the one number that would make two offers comparable is missing.

What stays legal, without decoration

This deserves to be said plainly, because it is the part most people who land here are actually looking for.

What does not exist

There is no legal alternative with a comparable psychoactive effect. Anyone announcing one is selling something else, or selling something that simply has not been named on a schedule yet.

What does exist

CBD, which is not psychotropic and therefore keeps its legal position. On the food side the novel food procedure remains open, which is a separate question from controlled substances.

Why CBD’s position is steadier

Because it rests on a European court ruling and on a finding that there is no psychotropic effect, not on a hole in a list. A hole gets filled; a criterion gets argued.

What we cannot say about CBD

Not a single health claim is authorised for cannabidiol in the European Union. Any sentence attributing an effect on the body to it goes further than the rules allow, and you will not find one here.

What the chemistry does not settle

This section matters even with a ban in place, because it describes an entire class of products that will keep coming back under new names.

What happens in the reaction

Hydrogenation runs with a catalyst under controlled conditions. Conversion is never complete: at the end of the process the target compound sits alongside unreacted starting material and the by-products of the reaction itself.

What remains beside the target compound

Catalyst residues, solvents from the purification step and intermediate compounds. None of them appears in the percentage printed on the label.

What the usual certificate shows

The content of the advertised molecule. Rarely the full impurity profile, which is precisely what would decide whether the product is acceptable.

What would have been needed

A per-batch impurity analysis with limits fixed in advance. It did not exist as an industry practice, and that is part of why these molecules ended up controlled.

Why the data is so thin

The same absence of data gets used in both directions, and neither use is honest.

History of consumption

Effectively nil before 2021. That is far too short a period to observe anything that shows up late.

Available studies

Few, mostly on the isolated molecule rather than on commercial mixtures with their real impurity profile. The distance between those two things is not a detail.

Notifications

European early-warning systems recorded signals from 2022, and those signals prompted the first national bans. A warning signal is not a study, but it is not nothing either.

What the absence means

Absence of data does not mean absence of risk, and it does not mean demonstrated risk. It means nobody knows, and that is the whole sentence.

Where the new acronyms come from

HHC-O, HHC-P, H4CBD, 10-OH-HHC, THCP: the list grows every few months, and the mechanism is worth understanding because it will repeat with the next name.

The mechanism is always the same

Schedules name molecules one at a time. Modify the structure just enough that the chemical name no longer matches the entry, and the product formally falls outside the schedule. Nothing about its effect changes, and nothing about the state of knowledge changes either.

Why regulators started answering differently

Because enumerating individual names was a losing race. The German amendment of 2 December 2025 brought in structural analogues rather than only named molecules. The Spanish order of April 2025 listed seven entries at once.

What that means for a buyer

That an acronym not yet scheduled is not a safer or better-studied version. It is a version even less is known about, precisely because it is newer.

Why it will keep happening

Because demand does not disappear when something is scheduled, and synthesis is cheap. Another acronym will arrive, and the descriptions will look exactly like the last ones. This paragraph is worth remembering for that moment.

What to ask before buying any cannabinoid

These four questions work just as well for CBD, and they separate a documented seller from one who improvises.

The legal status in the destination country

Not in the seller’s country. The correct answer arrives with a date and a reference to a rule; anything else is a commercial opinion.

The certificate for the specific batch

Not a generic certificate for the range, and not one from two years ago. The batch number on the certificate has to match the number printed on the package you receive.

The impurity profile

For any molecule obtained by chemical conversion, the declared content is not the relevant figure: what sat next to it is. Asking the question is usually enough to find out whether it exists.

What to do if there is no answer

Do not buy. A simple question with no clear answer is already sufficient information, and it saves the later argument about returns.

Frequently asked questions

Does HHC show up on a drug test

Common immunoassay tests detect THC metabolites and can cross-react with structurally similar molecules. Test manufacturers do not state a sensitivity for HHC, so the answer is that it varies and that no plan should be built on it.

Does a ban cover flower as well

The rules attach to the molecule, whatever carries it. Flower sprayed with distillate is a carrier of the substance and is assessed on the presence of that substance, not on its appearance.

Will CBD be banned too

Nothing indicates it, and the legal basis is different: cannabidiol is not psychotropic, as the Court of Justice of the European Union established. What remains open is the novel food procedure, which concerns food trading rather than controlled-substance schedules.

What should be done with a product already at home

Do not use it, do not resell it and do not post it on: supply is assessed separately and more severely than possession. Beyond that, the answer depends on circumstances that a web page cannot weigh.

What this page does not decide

Whether it is safe

We do not know, and anyone asserting the opposite in either direction is going further than the published data allows.

Whether the status will change

International listings are reviewed, like all of them. Nothing today points to movement in that direction, and that is why this page carries a date.

What effect it produces

We do not describe it. No authorised claim exists for these molecules in the European Union, and a description of effects would be exactly that.

What we recommend

Nothing from this family. We do not reference it in any market, and this page exists to answer someone arriving in search of it, not to accompany it.

In short

The international position

Schedule II of the 1971 Convention since 6 December 2025. The first semi-synthetic cannabinoid to get there, and the reason the country-shopping question is closed.

The national positions

Banned on different dates across Europe, from May 2023 in Denmark to May 2026 in Portugal — with Croatia covering it before it ever arrived. The dates differ; the direction never did.

What is left of the episode

One argument fewer: “it isn’t on the list” has stopped working as a guarantee. And a suspicion transferred to CBD, which was never in the same legal position.

The practical consequence

If you were looking for where to buy it, the answer is that there is no legal where. If you were trying to understand why it vanished from serious shops, you now have it with dates and references.